Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hoth Therapeutics Inc HOTH

Healthcare
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s... see more

Recent & Breaking News (NDAQ:HOTH)

Voltron Therapeutics, Inc. Executes Manufacturing Agreement with Global Pharmaceutical Contract Development and Manufacturing Organization

GlobeNewswire September 16, 2020

Voltron Therapeutics, Inc. Announces Completion of First Small Animal Safety and Immunogenicity Study Assessing the Effect of Novel COVID-19 Vaccine, HaloVax(TM)

GlobeNewswire September 15, 2020

Hoth Therapeutics' Chief Scientific Officer, Dr. Stefanie Johns, to Appear on One America News Network on Tuesday, September 1, 2020

PR Newswire September 1, 2020

LD Micro -- 360 Companies Set to Present this Week

Accesswire August 31, 2020

Hoth Therapeutics Appoints Stefanie Johns, Ph.D., as Chief Scientific Officer

PR Newswire August 31, 2020

Hoth Therapeutics Announces Participation at Upcoming Investor Conferences in September

PR Newswire August 28, 2020

Laidlaw Venture Partners Hosts Panel Discussion "Cutting Edge Perspectives on the Latest Developments in COVID-19 Vaccine Development Strategy"

GlobeNewswire August 25, 2020

Hoth Therapeutics Provides Shareholder Update on COVID-19 Initiatives and Dermatological Therapy Pipeline

PR Newswire August 19, 2020

Hoth Therapeutic Announces That It Has Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis

PR Newswire August 13, 2020

Hoth Therapeutics to Participate in LD Micro's Zooming with LD, August 11th 8 AM PDT

Accesswire August 10, 2020

Hoth Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device

PR Newswire August 10, 2020

LD Micro - Announces Preliminary List of Presenters for the LD-500

Accesswire August 5, 2020

Hoth Therapeutics Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological Diseases

PR Newswire July 31, 2020

Registration for Sidoti's 2020 Fall Virtual Investor Conference is Now Open

Accesswire July 30, 2020

Voltron Therapeutics Retains Buenaventura Advisors, LLC to Explore Strategic Alternatives for its HaloVax(TM) Subsidiary

GlobeNewswire July 9, 2020

Voltron Therapeutics, Inc. Initiates Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19

GlobeNewswire July 8, 2020

Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment

PR Newswire June 30, 2020

Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University for Dermatology Treatment Candidate WEG232

PR Newswire June 16, 2020

Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White Paper

PR Newswire June 15, 2020

Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology Conditions

PR Newswire June 8, 2020